Heart Failure Perspective

 
 
  • NOACs for Preventing Stroke in AF An elderly woman presents with AF in the setting of heart failure. How would you manage her anticoagulation?
  • Sodium Restriction in HF: Take It With a Grain of Salt?   Despite wide acceptance, evidence to support low-sodium diets is lacking. Until we know more, keep dietary recommendations simple, says Ileana Piña, MD.
  • Hyperglycemia in T2D: Where's the Proof of the Pudding? Have older medications been justifiably sidelined in the ADA/EASD consensus statement on managing hyperglycemia in type 2 diabetes? Dr Aus Alzaid shares his critique of the updated guideline.
  • Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?   A new consensus document from ACC acknowledges the 'twofer' benefits of some antidiabetic drugs.
  • The Top Cardiology Trials of 2018 in Review Contrasting studies on the benefits of percutaneous mitral valve repair and a fall from grace for aspirin make the list for Bob Harrington and Mike Gibson. Find out what else piqued their interest.
  • Mandrola's Top 10 Cardiology Stories of 2018 From blood pressure management in the community to a study on potentially biased referees -- John Mandrola reviews his picks for the year's big stories in cardiology and medicine.
  • Do Neprilysin Inhibitors Have a Role in Patients With CKD? Dr Desai reviews the UK HARP-III trial, which compares the effects of sacubitril/valsartan and irbesartan on kidney function in people with CKD.
  • Cardiovascular Outcomes Trials Give 'Comforting' Results   Dr Anne Peters gives us her take on the recent CARMELINA, DECLARE-TIMI, and REWIND trials and their cardiovascular outcomes.
  • Does PIONEER-HF Warrant Acute HF Indication for ARNI?   Drs Pina and Butler discuss the new findings of PIONEER-HF, a trial evaluating angiotensin-neprilysin inhibition in acute heart failure.
  • SGLT2 Inhibitors: Is This the Start of a New Era? Gregory Nichols discusses exciting new clinical trial results demonstrating the benefits of SGLT2 inhibitors, as presented at the AHA 2018 Scientific Sessions.
  • Viral Hepatitis: Five Highlights From the Liver Meeting Dr William Balistreri reports on the most important viral hepatitis news from this year's Liver Meeting.
  • PIONEER: A Role for ARNI in Stabilized Acute HF?   Sacubitril/valsartan (Entresto) was studied in patients with acute decompensated heart failure in the PIONEER HF Trial. Dr Piña gets the details from lead investigator Eric Velazquez.
  • Top News From AHA 2018: Slideshow Highlights include new guidelines on cholesterol management and physical activity, plus potentially practicing changing results with high-dose omega-3 for CVD prevention.
  • AHA 2018Think You're Immune From Bias? Think Again John Mandrola, MD, is intrigued by two studies at AHA that track the cognitive and financial biases that may influence what physicians do in practice and how they write and read research papers.
  • AHA 2018Glad Your EF Is Better, But Stay on Your Meds While the TRED-HF trial may not be great news for patients with dilated cardiomyopathy and recovered EF, at least it eases this physician's conscience about her reluctance to curtail pharmacotherapy.
  • What Cardiologists Should Know About Obesity   Cardiologist Seth Baum interviews obesity experts Drs Kahan and Apovian, who dispel the myth of the 'obesity paradox' and the 'metabolically healthy obese,' and any fears about treating this disease.
  • Echocardiography: The Good, the Bad, and the Ugly Echocardiography is a great tool when used appropriately, but Melissa Walton-Shirley, MD, finds that poor-quality images and scanty reports often cause more confusion than clarity.
  • Malpractice Case: Here's Where Procedure Errors Often Occur Physicians rely on their staff to complete all necessary paperwork, but patients often hold doctors responsible for completing this task.
  • Prevention of Type 2 Diabetes Highlighted at EASD 2018 Dietary changes and regular exercise are proven interventions that reduce the risk for type 2 diabetes, but with rates of obesity on the rise, other strategies may be required.
  • Oral Antibiotics for Infective Endocarditis: Time to Switch?   The standard of care for endocarditis for many years has been IV antibiotics, even though many patients don't complete the full treatment. Would oral antibiotics work just as well?